CRNX · Crinetics Pharmaceuticals, Inc.

Track CRNX — free

$84.95 +0.11 (+0.13%) At close · Aug 31

Rebalance outlook locked

Market Cap

$9.01B

106.07M

Up next

Next earnings call

Oct 8, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$42.16M

Trailing 12 months

Net income (TTM)

−$501.61M

Trailing 12 months

Revenue growth YoY

+2,336.3%

Year over year

Operating margin

-1,302.5%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-4.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$1.21B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+12.5%

Year over year · more shares

Price change (1Y)

+174.1%

Trailing year

Short interest

—

Latest settlement

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +88%

above

Price vs 50-day avg +69%

above

RSI (14) 93

overbought

MACD trend Negative

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +131%

trailing

6-month return +72%

trailing

YTD return +82%

this year

Relative strength +59%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $50 › 200d $45 — 50d above 200d

Institutional flow Accumulating

+9% holders QoQ · +56 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.21% of float · ▲ +12.3% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

268 holders — near 3-yr high, broad support

Fundamentals

Poor

Revenue growth −74%

Y/Y

EPS growth −34%

Y/Y

Free cash flow $-383.7M

Quant / Vol

risk profile

Very High

Volatility 114%

annualized · 1-yr

Max drawdown −42%

past year

ATR 2.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed May 7, 2026

GAAP operating expenses · 2026 $600M – $650M

Non-GAAP operating expenses · 2026 $480M – $520M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+88% Bullish

Price vs 50-day avg

+69% Bullish

RSI (14)

93 Bearish

MACD trend

Negative Bearish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $50 › 200d $45 — 50d above 200d

Institutional flow Accumulating

+9% holders QoQ · +56 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.21% of float · ▲ +12.3% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

268 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $33 Now $85 · 100% Range high $85

vs 200-day avg +88% vs 50-day avg +69%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRNX Crinetics Pharmaceuticals, Inc. this stock	$9.01B	+82.5%	-74.1%	—	6.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

268

% held: 116.7%
Net QoQ: +857.4K sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

320

View

Short & Settlement

Short Interest Rising

Shares short

6.6M

Days to cover: 3.1d
Change: +722.3K sh

View

Short Volume

Short vol %

53%

As of: Aug 31, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.5K
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

36.4%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Mar 3, 2026

View

Financials

Revenue (FY)

$7.7M

Net income (FY): $-465.3M
EPS diluted: $-4.95

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 1, 2026
This year: 21

View

Proposed Sales

Value

$1.8M

Shares: 47.4K
Filed: Jul 2, 2026

View

Exempt Offerings

Offering

$350.0M

Filed: Mar 11, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 28, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CRNX	+0.2%	+131.5%	+72.1%	+1.3%	+82.5%
SPY	+0.5%	+1.2%	+13.3%	+2.7%	+12.5%
vs SPY	-0.3%	+130.2%	+58.9%	-1.4%	+70.0%

Key facts CIK 1658247 CUSIP 22663K107 13F (30d) 121 filings 121 filers Visit website Investor relations

CRNX · Crinetics Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance